ACC 2021: Key Studies Affecting Clinical Care of Heart Failure
  • CME

May 15-17, 2021; Virtual
Read these expert commentaries from Dr. Lee R. Goldberg and Dr. James Udelson detailing how new data on heart failure treatment presented at ACC 2021 will affect clinical practice.
Lee R. Goldberg, MD, MPH, FACC
James Udelson, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: July 28, 2021 Expiration: July 27, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the latest data on SGLT2 inhibition in HF and implications in patient management.
  • Discuss the latest data from clinical trials on new and investigational drugs for HF with reduced ejection fraction and potential implications in patient care.
  • Discuss the latest data from clinical trials of HF with preserved ejection fraction and potential implications in patient management.

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Lee R. Goldberg, MD, MPH, FACC

Professor of Medicine
Division of Cardiovascular Medicine
Department of Medicine
Section Chief, Advanced Heart Failure and Cardia Transplant
Division of Cardiovascular Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Lee R. Goldberg, MD, MPH, has disclosed that he has received funds for contracted research for Respircardia and has received consulting fees from Abbott, Respircardia, and Viscardia.
James Udelson, MD

Professor of Medicine and Radiology
Department of Medicine
Tufts University School of Medicine
Chief, Division of Cardiology
CardioVascular Center
Tufts Medical Center
Boston, Massachusetts

James Udelson, MD, has disclosed that he has received funds for contracted research for Cytokinetix and has received consulting fees from Cardurion, LivaNova, and Merck.

Staff

Susan Daniels, PhD
Scientific Director
Susan Daniels, PhD, has no relevant conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with HF.

Goal

The goal of this activity is to improve the knowledge and competence of learners to translate the most clinically important data from ACC 2021 into practical management of patients with HF.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 28, 2021, through July 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Dr. Lee R. Goldberg discusses key studies from ACC 2021 that will impact heart failure management, as reported by Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Released: July 15, 2021

From Clinical Care Options (CCO) and Dr. James Udelson, expert commentary on new data in heart failure management from ACC 2021

James Udelson, MD Released: July 14, 2021

From Clinical Care Options (CCO), new data from ACC 2021 on SGLT2 inhibitors in heart failure

Released: July 1, 2021

Latest data on empagliflozin in routine care of patients with type 2 diabetes from ACC 2021 reported by Clinical Care Options (CCO)

Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue